Céline Mirjolet
Céline Mirjolet is an expert in Radiotherapy at Centre Georges François Leclerc (France). Céline Mirjolet has authored 104 publications, the most recent in 2025, and is an investigator in 1 clinical trial, 1 of them ongoing. SLR score: 450 (community average: 125). How the SLR is computed.
LeadR Profile
Radiotherapy
Subspecialties: Oncology - Biochemistry - Immunology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2002 - 2026
Number : 104
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| A Modular Supramolecular Peptide Platform Reveals Atomic-Number-Dependent Mechanisms Driving Radioenhancement. PMID 41259368 — neoplasms, therapeutics, nanotechnology | ACS Nano | 2025 | 0 |
| Guidelines about radiotherapy and oncologic systemic treatments: Stop or continue? PMID 41106037 — radiotherapy, therapeutics | Cancer Radiother | 2025 | 0 |
| Tumour and normal tissue radiosensitivity: 2025 update. PMID 40939263 — radiotherapy, radiation tolerance, neoplasms, prostate, prostatic neoplasms, therapeutics, tissues | Cancer Radiother | 2025 | 0 |
| Reinforced Polymer-Nanoparticle Hydrogels for Subcutaneous and Sustained Delivery of Trastuzumab. PMID 40489148 — hydrogels, polymers, nanoparticles, immunotherapy, therapeutics, trastuzumab | Adv Healthc Mater | 2025 | 6 |
| Mechanisms of Action of AGuIX as a Pan-Cancer Nano-Radiosensitizer: A Comprehensive Review. PMID 40283954 — radiotherapy, cells, nanomedicine, nanoparticles, neoplasms, ferroptosis, radiobiology, immunity, retention, psychology, cell death | Pharmaceuticals (Basel) | 2025 | 0 |
Clinical Studies 1
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
Ongoing trial started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Study Evaluating the Safety and the Efficacy of Combination of Atezolizumab Tiragolumab and and Stereotactic Body Radiation Therapy in Patients With Oligometastatic Multiorgan (IMMUNOs SBRT) NCT05259319 — radiotherapy, urinary bladder, urinary bladder neoplasms, cells, lung, safety, neoplasms, multiple chronic conditions, carcinoma, non-small-cell lung, carcinoma, renal cell, solutions, lung neoplasms, small cell lung carcinoma, head and neck neoplasms, therapeutics, carcinoma | Phase 1 | Recruiting | 2022 |
LeadR Networks
Main global connection map